318 related articles for article (PubMed ID: 20503282)
1. Pulmonary exacerbations in cystic fibrosis with negative bacterial cultures.
Zemanick ET; Wagner BD; Harris JK; Wagener JS; Accurso FJ; Sagel SD
Pediatr Pulmonol; 2010 Jun; 45(6):569-77. PubMed ID: 20503282
[TBL] [Abstract][Full Text] [Related]
2. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
Jain K; Wainwright C; Smyth AR
Cochrane Database Syst Rev; 2013 Dec; (12):CD009530. PubMed ID: 24363033
[TBL] [Abstract][Full Text] [Related]
3. Bronchoscopy-guided antimicrobial therapy for cystic fibrosis.
Jain K; Wainwright C; Smyth AR
Cochrane Database Syst Rev; 2016 Jan; (1):CD009530. PubMed ID: 26797965
[TBL] [Abstract][Full Text] [Related]
4. Nebulized tobramycin in the treatment of adult CF pulmonary exacerbations.
Al-Aloul M; Nazareth D; Walshaw M
J Aerosol Med Pulm Drug Deliv; 2014 Aug; 27(4):299-305. PubMed ID: 24219814
[TBL] [Abstract][Full Text] [Related]
5. The efficacy and safety of meropenem and tobramycin vs ceftazidime and tobramycin in the treatment of acute pulmonary exacerbations in patients with cystic fibrosis.
Blumer JL; Saiman L; Konstan MW; Melnick D
Chest; 2005 Oct; 128(4):2336-46. PubMed ID: 16236892
[TBL] [Abstract][Full Text] [Related]
6. Oral Azithromycin and Response to Pulmonary Exacerbations Treated with Intravenous Tobramycin in Children with Cystic Fibrosis.
Klingel M; Stanojevic S; Tullis E; Ratjen F; Waters V
Ann Am Thorac Soc; 2019 Jul; 16(7):861-867. PubMed ID: 30874447
[No Abstract] [Full Text] [Related]
7. Reduction in Pseudomonas aeruginosa sputum density during a cystic fibrosis pulmonary exacerbation does not predict clinical response.
Lam JC; Somayaji R; Surette MG; Rabin HR; Parkins MD
BMC Infect Dis; 2015 Mar; 15():145. PubMed ID: 25887462
[TBL] [Abstract][Full Text] [Related]
8. Oral Azithromycin Use and the Recovery of Lung Function from Pulmonary Exacerbations Treated with Intravenous Tobramycin or Colistimethate in Adults with Cystic Fibrosis.
Somayaji R; Russell R; Cogen JD; Goss CH; Nick SE; Saavedra MT; Taylor-Cousar JL; Nick JA; Nichols DP
Ann Am Thorac Soc; 2019 Jul; 16(7):853-860. PubMed ID: 30840835
[No Abstract] [Full Text] [Related]
9. Long-term effects of azithromycin in patients with cystic fibrosis.
Samson C; Tamalet A; Thien HV; Taytard J; Perisson C; Nathan N; Clement A; Boelle PY; Corvol H
Respir Med; 2016 Aug; 117():1-6. PubMed ID: 27492507
[TBL] [Abstract][Full Text] [Related]
10. Effect of azithromycin on pulmonary function in patients with cystic fibrosis uninfected with Pseudomonas aeruginosa: a randomized controlled trial.
Saiman L; Anstead M; Mayer-Hamblett N; Lands LC; Kloster M; Hocevar-Trnka J; Goss CH; Rose LM; Burns JL; Marshall BC; Ratjen F;
JAMA; 2010 May; 303(17):1707-15. PubMed ID: 20442386
[TBL] [Abstract][Full Text] [Related]
11. Induced sputum compared to bronchoalveolar lavage in young, non-expectorating cystic fibrosis children.
Blau H; Linnane B; Carzino R; Tannenbaum EL; Skoric B; Robinson PJ; Robertson C; Ranganathan SC
J Cyst Fibros; 2014 Jan; 13(1):106-10. PubMed ID: 23806622
[TBL] [Abstract][Full Text] [Related]
12. Combination antimicrobial susceptibility testing for acute exacerbations in chronic infection of Pseudomonas aeruginosa in cystic fibrosis.
Waters V; Ratjen F
Cochrane Database Syst Rev; 2015 Nov; (11):CD006961. PubMed ID: 26522473
[TBL] [Abstract][Full Text] [Related]
13. Initial Pseudomonas aeruginosa treatment failure is associated with exacerbations in cystic fibrosis.
Mayer-Hamblett N; Kronmal RA; Gibson RL; Rosenfeld M; Retsch-Bogart G; Treggiari MM; Burns JL; Khan U; Ramsey BW;
Pediatr Pulmonol; 2012 Feb; 47(2):125-34. PubMed ID: 21830317
[TBL] [Abstract][Full Text] [Related]
14. Inflammation and airway microbiota during cystic fibrosis pulmonary exacerbations.
Zemanick ET; Harris JK; Wagner BD; Robertson CE; Sagel SD; Stevens MJ; Accurso FJ; Laguna TA
PLoS One; 2013; 8(4):e62917. PubMed ID: 23646159
[TBL] [Abstract][Full Text] [Related]
15. Early anti-pseudomonal acquisition in young patients with cystic fibrosis: rationale and design of the EPIC clinical trial and observational study'.
Treggiari MM; Rosenfeld M; Mayer-Hamblett N; Retsch-Bogart G; Gibson RL; Williams J; Emerson J; Kronmal RA; Ramsey BW;
Contemp Clin Trials; 2009 May; 30(3):256-68. PubMed ID: 19470318
[TBL] [Abstract][Full Text] [Related]
16. Molecular analysis of changes in Pseudomonas aeruginosa load during treatment of a pulmonary exacerbation in cystic fibrosis.
Reid DW; Latham R; Lamont IL; Camara M; Roddam LF
J Cyst Fibros; 2013 Dec; 12(6):688-99. PubMed ID: 23706827
[TBL] [Abstract][Full Text] [Related]
17. Acute effects of viral respiratory tract infections on sputum bacterial density during CF pulmonary exacerbations.
Chin M; De Zoysa M; Slinger R; Gaudet E; Vandemheen KL; Chan F; Hyde L; Mah TF; Ferris W; Mallick R; Aaron SD
J Cyst Fibros; 2015 Jul; 14(4):482-9. PubMed ID: 25544473
[TBL] [Abstract][Full Text] [Related]
18. Long-term azitromycin treatment of cystic fibrosis patients with chronic Pseudomonas aeruginosa infection; an observational cohort study.
Hansen CR; Pressler T; Koch C; Høiby N
J Cyst Fibros; 2005 Mar; 4(1):35-40. PubMed ID: 15752679
[TBL] [Abstract][Full Text] [Related]
19. Long term azithromycin therapy in patients with cystic fibrosis.
Emiralioğlu N; Öztürk Z; Yalçın E; Doğru D; Özçelik U; Kiper N
Turk J Pediatr; 2016; 58(1):34-40. PubMed ID: 27922234
[TBL] [Abstract][Full Text] [Related]
20. Are antipseudomonal antibiotics really beneficial in acute respiratory exacerbations of cystic fibrosis?
Wolter JM; Bowler SD; McCormack JG
Aust N Z J Med; 1999 Feb; 29(1):15-21. PubMed ID: 10200808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
